Medpace Holdings, Inc. (MEDP)
- Previous Close
288.77 - Open
293.79 - Bid 299.24 x 100
- Ask 300.62 x 100
- Day's Range
292.11 - 300.46 - 52 Week Range
250.05 - 459.77 - Volume
456,889 - Avg. Volume
527,445 - Market Cap (intraday)
8.622B - Beta (5Y Monthly) 1.55
- PE Ratio (TTM)
22.88 - EPS (TTM)
13.11 - Earnings Date Jul 21, 2025 - Jul 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
300.30
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
www.medpace.com5,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MEDP
View MorePerformance Overview: MEDP
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MEDP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MEDP
View MoreValuation Measures
Market Cap
8.62B
Enterprise Value
8.31B
Trailing P/E
22.90
Forward P/E
24.39
PEG Ratio (5yr expected)
3.45
Price/Sales (ttm)
4.43
Price/Book (mrq)
14.53
Enterprise Value/Revenue
3.85
Enterprise Value/EBITDA
17.11
Financial Highlights
Profitability and Income Statement
Profit Margin
19.31%
Return on Assets (ttm)
15.44%
Return on Equity (ttm)
65.82%
Revenue (ttm)
2.16B
Net Income Avi to Common (ttm)
416.39M
Diluted EPS (ttm)
13.11
Balance Sheet and Cash Flow
Total Cash (mrq)
441.44M
Total Debt/Equity (mrq)
25.33%
Levered Free Cash Flow (ttm)
433.28M